Article

Warburg Pincus completes acquisition of Bausch & Lomb

New York-Affiliates of private equity firm Warburg Pincus have completed the acquisition of Bausch & Lomb (B&L) for approximately $4.5 billion, including about $830 million of debt.

New York

-Affiliates of private equity firm Warburg Pincus have completed the acquisition of Bausch & Lomb (B&L) for approximately $4.5 billion, including about $830 million of debt.  

“With a strong and supportive partner in Warburg Pincus, we are well-positioned to create new opportunities for [B&L] and advance our leadership in the eye health industry,” said Ronald L. Zarrella, chairman and chief executive officer of B&L, Rochester, NY.
 
Elizabeth H. Weatherman, a Warburg Pincus managing director, said, “We look forward to helping the company build upon its rich heritage and premier brand in ophthalmology.”

B&L stock has been delisted on the New York Stock Exchange. Under the terms of the acquisition agreement, B&L shareholders are entitled to receive $65 in cash for each share of B&L common stock that they hold.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.